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A genome-wide association study identified single nucleotide polymorphisms (SNPs) rs3077 and rs9277535 located in the
30 untranslated regions of human leukocyte antigen (HLA) class II genes HLA-DPA1 and HLA-DPB1, respectively, as the
independent variants most strongly associated with chronic hepatitis B. We examined whether these SNPs are associated with
mRNA expression of HLA-DPA1 and HLA-DPB1. We identified gene expression-associated SNPs (eSNPs) in normal liver
samples obtained from 651 individuals of European ancestry by integrating genotype (B650000 SNPs) and gene expression
(439000 transcripts) data from each sample. We used the Kruskal–Wallis test to determine associations between gene
expression and genotype. To confirm findings, we measured allelic expression imbalance (AEI) of complementary DNA
compared with DNA in liver specimens from subjects who were heterozygous for rs3077 and rs9277535. On a genome-wide
basis, rs3077 was the SNP most strongly associated with HLA-DPA1 expression (p¼10
 48), and rs9277535 was strongly
associated with HLA-DPB1 expression (p¼10
 15). Consistent with these gene expression associations, we observed AEI for
both rs3077 (p¼3.0 10
 7; 17 samples) and rs9277535 (p¼0.001; 17 samples). We conclude that the variants previously
associated with chronic hepatitis B are also strongly associated with mRNA expression of HLA-DPA1 and HLA-DPB1,
suggesting that expression of these genes is important in control of HBV.
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Introduction
Chronic infection with hepatitis B virus (HBV) is the
most common cause of liver cancer worldwide, as well as
a major risk factor for development of cirrhosis and end-
stage liver disease.
1 The hepatitis B vaccine is highly
effective in preventing new infections, but B360 million
people still suffer from chronic hepatitis B and there are
B600000 annual deaths from HBV-related causes.
1
Recent genome-wide association studies identified single
nucleotide polymorphisms (SNPs) located within the
human leukocyte antigen (HLA) class II genes HLA-
DPA1 and HLA-DPB1 to be associated with chronic
hepatitis B.
2,3 Replication studies performed on two of
these SNPs (rs3077 and rs9277535) confirmed and
strengthened results from the genome-wide association
studies.
2 Class II HLA genes encode proteins expressed
on the surface of antigen-presenting cells such as
macrophages, dendritic cells and B cells, and thereby
have a critical role in presentation of antigens to CD4
þ
T-helper lymphocytes. HLA genes have many structural
variants that have been linked to immune response to
infectious agents,
4 but genetic variants that influence
HLA mRNA expression might also affect antigen
presentation and many ‘gene expression-associated
SNPs’ (eSNPs) have been found for HLA genes.
5,6 An
integrated approach combining genotype information
with genome-wide gene expression data in relevant
tissues can identify genetic variations that are both
regulatory and disease causing.
6,7 In this study, we
examined whether SNPs implicated in chronic hepatitis
B are associated with mRNA expression in liver samples
from the Human Liver Cohort, a large study of genotype
and gene expression in normal liver.
6 Additionally,
we performed confirmatory allelic expression imbalance
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www.nature.com/gene(AEI) studies in human liver and peripheral blood.
We found that SNPs associated with chronic hepatitis B
are strongly associated with decreased expression of
important antigen-presenting molecules, HLA-DPA1 and
HLA-DPB1.
Results
Genetic variants and mRNA expression
A published genome-wide association study for chronic
hepatitis B identified 11 disease-associated SNPs; con-
firmatory replication studies were performed on rs3077
and rs9277535 (ref. 2). SNP rs3077 is located in the 30
untranslated region (30 UTR) of HLA-DPA1, rs2395309
lies B6.5kb downstream of HLA-DPA1 and rs2301220 is
found in the first intron of HLA-DPA1. These SNPs are in
complete linkage disequilibrium (LD) in Europeans
(CEU HapMap samples, r
2¼1.0; Figure 1a) and in near
complete LD in Asians (JPTþCHB HapMap samples,
r
2¼0.93–0.97, Figure 1b). Among the B650000 SNPs that
were genotyped and examined for association
with expression of HLA-DPA1, rs2395309, rs3077 and
rs2301220 were the variants most strongly associated
with mRNA expression of this gene (pB10
 48; Table 1).
Of the eight remaining SNPs that were associated with
chronic hepatitis B,
2 five were associated with expression
of HLA-DPA1 as well (Table 1).
Figure 2a shows odds ratios for chronic hepatitis B
2
and differences in mean-log gene expression by rs3077
genotypes. Gene expression was measured relative to a
pool of control liver samples,
6 and the risk genotype
Figure 1 LD (r
2) between SNPs associated with chronic hepatitis B: (a) European samples (CEU, HapMap); (b) Asian samples (JPTand CHB,
HapMap).
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The rs3077-G allele was associated with both higher risk
of chronic hepatitis B and lower expression of HLA-DPA1
in a pattern consistent with an additive genetic model.
Similarly, SNP rs9277535, located within the 30 UTR of
HLA-DPB1 (B22kb from rs3077), was strongly asso-
ciated with both increased risk of chronic hepatitis B and
decreased expression of HLA-DPB1 (p¼10
 15; Table 1,
Figure 2b). There is only weak LD between rs9277535
and rs3077 in Europeans (r
2¼0.09, D0 ¼0.50; HapMap
CEU; Figure 1a) and Asians (r
2¼0.24, D0 ¼0.54; HapMap
JPTþCHB; Figure 1b), suggesting that effects of these
SNPs are likely to be independent.
To confirm that rs3077 and rs9277535 are associated
with increased mRNA expression of their respective
genes, we also examined genotype and gene expression
data from a publically available database of 400 Epstein-
Barr virus-transformed lymphoblastoid cell lines ob-
tained from British children with asthma.
5 Among these
subjects, rs3077 was strongly associated with HLA-DPA1
expression (p¼10
 21) and rs9277535 with HLA-DPB1
expression (p¼10
 12).
Allelic expression imbalance
In the Human Liver Cohort, mRNA expression was
measured by a microarray. It has been suggested that
genetic and structural variations within the HLA region
could affect efficiency of hybridization of microarray
probes,
8,9 and, if so, differences in mRNA levels could
reflect differences in detection efficiency rather than true
differences in gene expression. We reasoned that if a
genetic variation is truly associated with altered gene
expression in cis, samples from heterozygous individuals
should display AEI in complementary DNA (cDNA)
when compared with DNA.
10 The location of rs3077 and
rs9277535 in transcribed (30 UTR) regions of HLA-DPA1
and HLA-DPB1 makes these SNPs good candidates for
AEI testing. Furthermore, AEI Taqman assays for these
SNPs were designed to avoid any other underlying
genetic variation in the amplicons. Therefore, AEI is an
independent test for possible differences in gene expres-
sion associated with genetic variants. Consistent with the
mRNA expression associations found in the Human
Liver Cohort, we observed AEI for both rs3077 (liver
tissue (n¼17), p¼3.0 10
 7, Figure 3a) and monocytes
((n¼22), p¼2.0 10
 8, Figure 3b) and rs9277535 (liver
Table 1 SNPs associated with chronic infection with HBV
2 and with mRNA expression of HLA-DPA1 and HLA-DPB1 in 651 human liver
tissue samples
SNPs HBV GWAS
2 HLA-DPA1 Expression in Liver HLA-DPB1 Expression in Liver Location within HLA region
P-value Rank P-value Rank P-value
rs2395309 1.16E-13 1 1.24E-48 NS DPA1, downstream
rs3077 1.59E-13 1 1.24E-48 NS DPA1, 30 UTR
rs2301220 1.81E-13 5 4.13E-47 NS DPA1, intron 1
rs9277535 2.14E-12 17 1.92E-08 2 2.28E-15 DPB1, 30 UTR
rs3117222 1.29E-10 14 9.76E-10 NS DPB1, downstream
rs3128917 1.98E-10 15 9.76E-10 NS DPB1, downstream
rs3135021 1.63E-08 NS NS DPB1, intron 1
rs9380343 1.66E-08 NS NS DPB2, upstream
rs9277341 1.84E-08 7 1.32E-22 NS DPA1, intron 1
rs10484569 2.34E-08 NS NS DPB1, downstream
rs2281388 3.62E-08 21 1.98E-06 NS DPB1, downstream
Abbreviations: GWAS, genome-wide association study; HBV, hepatitis B virus; HLA, human leukocyte antigen; SNPs, single nucleotide
polymorphisms.
Rank indicates position among all cis SNPs that were tested for expression; P-values are for association of SNPs with chronic hepatitis B based
on the GWAS
2 or with gene expression; NS indicates a non-significant P-value (45.0 10
 5 for cis-effect (probe to SNP distance o1Mb)).
Figure 2 Association of rs3077 and rs9277535 with risk of chronic
HBV infection
2 (blue) and mRNA expression of HLA-DPA1 and
HLA-DPB1 in 651 human liver tissue samples from the Human
Liver Cohort (red).
6 (a) Odds ratios for chronic HBV
2 and difference
in expression of HLA-DPA1 in liver tissue, by rs3077 genotype. (b)
Odds ratios for chronic HBV
2 and difference in expression of HLA-
DPB1 in liver tissue, by rs9277535 genotype. Gene expression values
represent the arithmetic increase in mean-log gene expression
compared with the risk genotype (rs3077GG or rs9277535GG)
groups.
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Genes and Immunitytissue (n¼17), p¼0.001, Figure 3c) and monocytes
((n¼17), p¼0.04, Figure 3d). For both SNPs, the pro-
portion of non-risk allele Awas significantly increased in
cDNA compared with DNA of heterozygous samples,
indicating reduced expression of the risk alleles. AEI for
rs3077 was not explained by rs9277535 and vice versa
(Supplementary Figure 1), although the statistical power
for those comparisons was more limited than for the
primary comparisons. Therefore, it is likely that rs3077
and rs9277535 (or variants in high LD with these
SNPs) exhibit independent effects on the expression of
HLA-DPA1 and HLA-DPB1, respectively.
Discussion
On the basis of findings for both genome-wide mRNA
expression and allelic expression imbalance, it seems that
SNPs rs3077 and rs9277535 are strongly associated with
regulation of HLA-DPA1 and HLA-DPB1, respectively.
Previous studies found that these SNPs were highly
associated with chronic HBV infection.
2,3 Together, these
independent studies strongly implicate lower expression
of HLA-DPA1 and HLA-DPB1 with increased risk of
chronic HBV.
HLA-DPA1 and HLA-DPB1 are expressed on the
surface of antigen-presenting cells. In the liver, expres-
sion of these proteins is likely to be limited to a small
population of Kupffer cells, the resident macrophages of
the liver. Kupffer cells are derived from blood mono-
cytes, and we observed evidence for AEI in both
monocytes and liver samples. We found that mRNA
expression of both HLA-DPA1 and HLA-DPB1 was low in
total human liver tissue, suggesting that it might be
limited to a specific sub-population of cells. We attemp-
ted to quantify protein expression in lysates from total
liver tissue, but failed to detect a measurable signal (data
not shown). Similarly, HLA-DPA1 and HLA-DPB1
protein expression was undetectable in liver tissue
examined by antibody-based proteomic methods.
11 It is
intriguing that the genetic risk variants associated with
chronic hepatitis B affect expression of the alpha (DPA)
and beta (DPB) chains of the same antigen-presenting
complex, as this suggests that insufficient expression of
either or both of these chains might result in the same
phenotype.
Kamatani et al.
2 reported that chronic hepatitis B was
associated with haplotypes comprised of rs3077-G,
rs9277535-G and certain structural variants of HLA-DPA1
and HLA-DPB1. Our findings do not exclude a role for
structural variants of HLA-DPA1 and HLA-DPB1 in
chronic hepatitis B, as viral control of HBV could be
affected by both regulatory and structural variants. For
example, functional variants of MBL2, which has an
important role in host defense against HIV-1 and other
infectious agents, include both regulatory and structural
variants.
12 On a genome-wide basis, rs3077 is the variant
most strongly associated with risk of chronic hepatitis B
and the variant most strongly associated with expression
of HLA-DPA1. It seems highly likely, therefore, that
expression of HLA-DPA1 has a role in the clearance of
HBV. Similarly, the association of rs9277535 with chronic
HBV and with HLA-DPB1 expression suggests that HLA-
DPB1 expression also contributes to chronic HBVinfection.
Kamatani et al.
2 noted that the HBV risk alleles for
rs3077 and rs9277535 are more common in Asians than
Europeans (fitting the global pattern for the epidemio-
logy of chronic hepatitis B). LD patterns in this genomic
region are very similar for populations of Asian or
European ancestry groups (Figures 1a and b), indicating
that the relationships between SNPs in this region are
comparable between these two ancestral groups even
though the allele frequencies differ.
We could not determine why the rs3077 and rs9277535
variants are associated with decreased mRNA expression
of HLA-DPA1 and HLA-DPB1 in liver, but variants within
Figure 3 AEI in heterozygous DNA and cDNA in human samples: (a) liver (n¼17) for rs3077; (b) liver (n¼17) for rs9277535; (c) monocytes
(n¼22) for rs3077; (d) monocytes (n¼19) for rs9277535.
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regulatory factors or regulation by microRNAs.
13 SNP
rs3077 was found to be associated with methylation level
of HLA-DPB1 and HLA-DPA1 in adult cerebellum
samples studied by Zhang et al.
14 (see Supplementary
Table 5 of that paper). It may also be noteworthy that
rs9277535 was linked to two different copy-number
variation regions in European HapMap subjects.
15
We did not observe any obvious factors that could
explain differential expression of HLA-DPA1 and
HLA-DPB1 mRNA, but future studies should address
this question.
SNPs rs3077and rs9277535 have been associated with
other diseases. The rs9277535 variant has been linked to
primary biliary cirrhosis.
16 Both rs3077 and rs9277535 have
been associated with rheumatoid arthritis,
17 although other
SNPs in the major histocompatibility complex class II
region were more strongly associated with that disease.
In conclusion, genetic variants previously associated
with chronic hepatitis B
2 are also associated with
decreased expression of an antigen-presenting complex
that consists of HLA-DPA1 and HLA-DPB1 chains.
Together, these independent studies strongly implicate
lower expression of HLA-DPA1 and HLA-DPB1 as a
factor for increased risk of chronic hepatitis B. Other
recent studies have demonstrated a relationship between
expression of HLA-C and control of HIV.
18,19 It is possible,
therefore, that HLA expression has a role in control of a
range of viruses. More broadly, our findings lend
support to the concept that SNPs identified through an
integrated genomic approach can provide both confirma-
tion and functional insights for disease associations.
6,20
If greater expression of HLA-DPA1 and HLA-DPB1
facilitate clearance of HBV infection, development of
therapies that increase expression of these genes might
aid in treatment of chronic hepatitis B.
Methods
Genome-wide association of SNPs with mRNA expression
As previously described,
6 the Human Liver Cohort
identifies eSNPs by integrating genotype and gene expres-
sion data for liver samples without evidence of liver
disease. The current analysis is based on 651 liver samples
obtained from patients of non-Hispanic European ancestry.
Genome-wide gene expression was measured with cus-
tom-designed Agilent (Agilent Technologies, Inc., Santa
Clara, CA, USA) arrays (439000 transcripts), and geno-
typing was performed with the Illumina (San Diego, CA,
USA) Sentrix HumanHap650Y genotyping chips.
6 The
Kruskal–Wallis test was used to determine association
between adjusted expression traits according to an additive
genetic model. False discovery rate threshold was set
at 10%. Associations were considered significant at
po5.0 10
 5 for cis–factors (probe to SNP distance
o1Mb) and po1.0 10
 8 for trans –factors.
6 Only SNPs
used both in genome-wide association studies for chronic
HBV
2 and the mRNA expression study
6 were used in this
analysis. For each of the SNPs, gene expression values were
compared with the referent non-risk genotypes.
Allelic expression imbalance
Liver tissue samples for AEI studies were non-cancerous
specimens provided by the Liver Tissue Cell Distribution
System (LTCDS). Anonymized fresh peripheral blood
samples from healthy donors were provided by the
Blood Bank at the NIH. Monocytes were purified from
fresh blood with CD14
þ-coated magnetic MicroBeads
with AutoMacs (Miltenyi Biotec, Auburn, CA, USA) as
previously described.
21 DNA from all samples was
prepared with DNAeasy kit (Qiagen, Valencia, CA,
USA) and RNA was prepared with Trizol reagent
(Invitrogen, Carlsbad, CA, USA) followed by RNAeasy
kit (Qiagen). The AEI was quantified with the allelic
discrimination genotyping assays C__11916951_10 for
rs3077 and a custom-designed assay for rs9277535. To
ensure that the signal was specific for cDNA and was not
derived from residual DNA in these samples, a ‘no
reverse-transcriptase’ control reaction was tested initi-
ally. Genotyping for all DNA and cDNA samples was
performed in duplicate on the 7900 Sequence Detection
System (ABI, Foster City, CA, USA).
AEI experiments were carried out as previously
described.
22,23 A standard curve was prepared based on
10 dilutions of two homozygous DNA samples prepared
from liver tissue, representing 5, 15, 25, 35, 45, 55, 65, 75,
85 and 95% of allele ‘X’, based on the standard curve. The
potential AEI in samples heterozygous for rs3077 and
rs9277535 was evaluated by comparing the proportion of
allele ‘X’ in DNA with that in cDNA with a paired two-
sided T-test. To evaluate the potential effect of one SNP
on AEI for the other (for example, effect of rs3077 on AEI
for rs9277535), we tested whether the proportion of allele
‘X’ in samples heterozygous for rs9277535 differed by the
genotype of rs3077. Using an F-test, we compared the
proportion of allele ‘A’ in all samples that were
heterozygous for rs9277535 with the proportion of allele
‘A’ in samples that were heterozygous for rs9277535, but
homozygous for rs3077.
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